Sangrix
SGRX
3 hedge funds and large institutions have $572K invested in Sangrix in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
1.27% less ownership
Funds ownership: 2.16% → 0.89% (-1.3%)
40% less funds holding
Funds holding: 5 → 3 (-2)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $318K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$148K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$84.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$84.2K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$1K |
SGRX Hedge Fund Activity: Q2 2021 in Review
3 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Sangrix (SGRX) for Q2 2021, worth a combined $572K — down 15% from $673K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SGRX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Squarepoint, exiting entirely with an estimated $148K sold.
- 3 institutional investors held Sangrix (SGRX) as of Q2 2021, down from 5 in Q1 2021.
- Funds reported $572K of Sangrix stock for Q2 2021, down 15% quarter-over-quarter.
- 0 funds opened new Sangrix positions in Q2 2021 and 2 closed out, a net change of -2 holders.
- The largest Sangrix seller in Q2 2021 was Squarepoint, an estimated $148K sold.
Based on aggregated 13F filings for Q2 2021.